SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20746)5/14/1998 10:28:00 AM
From: John O'Neill  Read Replies (1) | Respond to of 32384
 
Henry..the FDA meeting today on ERGO will probably indicate
prospects for approval/disapproval today?

I plan to attend the LGND annual meeting later this months.
Anyone else going?

JOO



To: Henry Niman who wrote (20746)5/14/1998 10:32:00 AM
From: D.Lu  Read Replies (1) | Respond to of 32384
 
A 14-month Phase 2 trial studying the interaction of the drugs adramycin and taxotere in treating breast cancer is seeking enrollees here. Earlier this was the site of research study conducted on tamoxifin. Is this latest trial somehow related to what Ligand is doing?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News